Rituximab versus placebo for maintenance in scleroderma lung disease
Treatments studied
Part of Skin clinical trials.
This study tests whether continuing rituximab (a medication that helps calm the immune system) every few months can keep lung scarring from getting worse in people with scleroderma. If you've already responded well to rituximab, this could help you maintain that improvement.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with systemic sclerosis (scleroderma) by a doctor.
- You must have lung scarring (interstitial lung disease) seen on a CT scan, with at least 10% of the lungs affected.
- You must have already received an initial treatment with rituximab infusions for this condition.
- Your lung function must have stayed stable after that initial treatment — no major drops in breathing tests.
- You need to have had all required vaccines at least 4 weeks before starting, and if you can get pregnant, you must use reliable birth control during the study and for 12 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This study tests an experimental cell therapy that targets your own immune cells to treat systemic sclerosis (scleroderma) with lung involvement. It aims to see if this treatment works better than standard care in reducing disease activity.
This study compares different treatment strategies for people with rheumatoid arthritis who also have interstitial lung disease (a type of lung scarring). It aims to find the best way to manage both conditions and potentially slow lung damage.
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
Hear when a new Systemic Sclerosis in Adults trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.